Report to the PBAC - Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease

2 November 2012

The draft report prepared for PBAC on the review of anti-dementia medicines for Alzheimers disease has been updated to include sub-committee and sponsor input. A plain language executive summary has been written, based on the full report for the PBAC, and is available for comment ahead of PBAC consideration. Further information can be found on the Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease page.